Introduction
Antithrombin III is a plasma glycoprotein that inhibits a number of serine proteases including those involved in blood coagulation (1) (2) (3) (4) (5) (6) . Congenital deficiencies or abnormalities of antithrombin III generally result in increased frequency of thrombotic episodes and underlines the importance of this inhibitor in hemostasis (7) . Several studies have detailed the reaction of antithrombin III in vitro with purified coagulation proteases (1) (2) (3) (4) (5) (6) . In these reactions, antithrombin III forms a stoichiometric covalent complex with the proteases. The rate of these reactions is accelerated by the presence of catalytic amounts of heparin (4, 8) .
Heparan sulfate proteoglycans have been isolated from cultured aortic endothelial cells (9) . Recent studies have suggested that these molecular species may be involved in the regulation of the coagulation cascade. Buonassisi and Colbern (10, I 1) have demonstrated that heparan sulfate proteoglycans from cultured rabbit endothelial cells inhibit the generation of thrombin but in an antithrombin-independent fashion. Busch and Owen (12) observed a small reduction in thrombin activity and a concomitant augmentation in thrombin-antithrombin complex formation when the enzyme and protease inhibitor were perfused through an isolated heart preparation or across a bed of cultured endothelial cells. However, these investigators could not unambiguously identify the molecular nature of the endothelial cell receptor which accelerated the above interaction and have claimed that it is not a heparin-like substance (13) . Rosenberg and colleagues (14, 15) have isolated heparin-like molecules from a variety of vascular tissues including those which have no mast cells and have demonstrated that these complex carbohydrates enhance the rate of inhibition of thrombin and Factor Xa by antithrombin in a fashion similar to commercial heparin. This group has also perfused the rat hindlimb preparation with thrombin and antithrombin and have shown that heparin-like molecules associated with the surface of the vasculature are able to accelerate enzymeinhibitor complex formation by as much as -20-fold (16) . Our previous study concerning the interaction of coagulation Factor Xa with the native endothelium ofbovine aortic segments showed that endogenous antithrombin III present on the vessel wall prevented Factor Xa binding and subsequent activation of prothrombin through the formation of a Factor Xa-antithrombin III complex (17) . This finding suggested that the intact vessel wall facilitated antithrombin III Following O-methylisourea treatment, antithrombin III had <8% of the initial heparin cofactor activity while progressive antithrombin III activity was >80% of the starting material. Tryptophan modification was carried out as previously described (24) .
Bovine Factor IX was purified to homogeneity (260 U/mg) by the method of Fujikawa et al. (25) and was activated by incubation with Factor XI. coupled to CNBr-Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) as described previously (26) . Factor (30) and by SDS-PAGE.
Monospecific antisera against antithrombin III were raised in rabbits by standard methods (31) . Immunoglobulin G from rabbit serum was purified using protein A-Sepharose CL-6B (Pharmacia Fine Chemicals) according to the manufacturer's recommendations. Protein concentrations were determined colorimetrically (32) and by active site titration with p-nitrophenyl-p'-guanidinobenzoate (33) . SDS-PAGE was carried out by the method of Laemmli (34) . Samples of vesselbound '5I-antithrombin III were prepared for SDS-PAGE by incubating the tissue segments for 20 min at 4°C with Tris-buffered saline containing 1% Nonidet P 40 (Sigma Chemical Co., St. Louis, MO), 10 mM EDTA, 2 mM phenylmethylsulfonyl fluoride (Sigma Chemical Co.), and 0.3 mM leupeptin (Boehringer Mannheim, Inc.). The eluate was then prepared for electrophoresis (34) .
Elution of endogenously bound antithrombin III from calf aortas was carried out on aortas excised immediately after slaughter. Vessels were washed four times with Tris-buffered saline and then incubated for 2 min at 21°C with Tris-buffered saline containing sodium heparin (Sigma Chemical Co.) at a concentration of 5 U. S. Pharmacopeia units/ml (150 U/mg). Heparin eluates were subjected to nonreduced SDS-PAGE (10%) by the method of Laemmli (34) (36) . Heparin titrations were carried out as described (16) . Bovine prothrombin and protein C were purified as described previously (37, 38) .
Bovine aortas. Thoracic aortas, a generous gift of the Great American Veal Co. (Newark, NJ), were obtained from 1-yr-old calves within 5 min postmortem. Sacrifice and exsanguination of the animals occurred simultaneously. This procedure was critical for obtaining intact aortic endothelium, as histological studies revealed a considerable number of adherent platelets as well as fibrin deposition on endothelium obtained from animals exsanguinated several minutes after sacrifice. Experiments were either performed immediately at the abbatoir or after transport to the laboratory (-40 min later). During transport, aortas were stored at 21 'C immersed in Hanks' balanced salt solution (Gibco Laboratories, Grand Island, NY) containing 25 mg/ml bovine serum albumin-fatty acid free. For binding and activation studies, the surrounding fat was removed and aortas were cut longitudinally between the intercostal vessels into 4.5 X 21-cm segments, spread flat, and placed within a lucite template. The lucite template consisted of two sheets of 0.5 in. thick lucite. The lower sheet was solid, and the upper sheet was prepared by drilling 0.79 cm2 holes at regularly spaced intervals. Aortic segments were placed on the lower sheet and covered with the upper sheet. The sheets fit closely together so that wells were formed by the holes in the upper sheet. No leakage from the wells was observed during the incubation period as >98% of the added radioactivity could be recovered. Control experiments were carried out in natural depressions in the vessel formed by resting the aorta on top of the upper sheet of the lucite template. Natural depressions of roughly the same volume as those generated by the 0.79 cm2 well area were selected. Additional experiments were performed directly on lucite sheets without aortas to exclude possible artifacts due to lucitecoagulation factor interaction.
Morphologic studies of the vessels were performed by scanning electron microscopy using standard procedures (37) .
Binding and inactivation studies on aortic segments. After the aorta was opened and placed beneath the template, each well was washed five times with incubation buffer over a total of 60 min to elute endogenously bound antithrombin III. Progressive loss of the protease inhibitor from the vessel by the wash procedure was assessed by radioimmunoassay (see below). The integrity of the endothelium was determined microscopically. In the next step, 0. 
Results
Microscopic study of calf aortas. Examination of the aortic segments by scanning electron microscopy revealed no evidence of cytoplasmic rupture, endothelial loss, exposure of the internal elastic laminae or adherent platelets (Fig. 1) . However, the cells did exhibit a protuberant character presumably resulting from lack of transmural pressure. Direct cell counts showed 1±0.04 X 106 cells/cm2 (mean±1 SD) vessel surface area.
Binding studies. Antithrombin III was eluted from vessel segments (Fig. 2 A) employing commercial heparin which dissociates vessel-associated inhibitor. Western blotting using a monospecific antibody to bovine antithrombin III indicated that the vessel-eluted material migrated identically to purified plasma antithrombin III on SDS-PAGE.
Binding of '251I-antithrombin III to the luminal surface of aortic segments was studied after extensive washing to remove endogenous protease inhibitor. Washing was considered complete when no antithrombin III was detectable by radioimmunoassay in eluates from representative wells incubated with heparin-containing (5 U/ml) incubation buffer (see below).
Incubation of 1251I-antithrombin III with the vessel segments demonstrated time-dependent binding (Fig. 3 A) . The Vessel-bound 1251-antithrombin III that eluted after 20 min with 1% Nonidet P-40 was identical to the initial tracer by SDS-PAGE (Fig. 2 B) . Neither 1251-antithrombin III in the supernatant following incubation with vessel segments nor vessel-bound antithrombin III exhibited any significant degradation after 40 min of incubation as judged by SDS-PAGE and precipitability in 5% trichloroacetic acid. The binding of 1251-antithrombin III to vessels was reversible (Fig. 3 B) (Fig. 3 B) .
Competitive binding studies (Fig. 5) showed inhibition of '251-antithrombin III-vessel (Fig. 4) . When the concentration of chondroitinases was increased to 3 U/ml, the incubation time 1 h, and the temperature to 370C, the results were unchanged. Modification of antithrombin III lysine residues by treatment with O-methylisourea also prevented subsequent 1251 -antithrombin Ill binding to vessels (Fig. 4) . Control shown.
vessel-mediated acceleration of Factor IX. inactivation. A similar acceleration of Factor X. inactivation by antithrombin III in the presence of vessels was observed (Fig. 6 B) . The cofactor effect of the vessel, however, appeared to be far less pronounced for Factor X. inactivation than that observed with Factor IXa. Controls in which Factor IX, and Factor X. were incubated with vessels under identical conditions to those employed in the experiments in Fig. 6 (Fig. 3) and addition of Factor X. accelerated dissociation of antithrombin III. This resulted in Factor Xa-antithrombin III complex detectable in the supernatants by SDS-PAGE, indicating that the vessel-bound inhibitor retained its anticoagulant activity. Further studies demonstrated enhancement of antithrombin III anticoagulant activity in the presence of vessels (Fig. 6) . Antithrombin III, which is not a potent inhibitor of Factor IXa in the absence of heparin, inactivated 50% of the added Factor IX, in 90 s in the presence of a vessel (Fig. 6 ).
Factor X. inactivation was also enhanced in the presence of aortas with 50% inhibition of the added Factor X. in 20 s compared with 2 min for the same degree of inactivation in the absence of vessels (Fig. 6) . (Fig. 5) . Chemical modification of antithrombin III lysine and tryptophan residues, which blocks its heparin cofactor activity (1), prevented subsequent antithrombin III-vessel wall binding (Fig. 5) (14) . In our studies, preincubation of vessel segments with dextran sulfate produced no detectable change in subsequent antithrombin III binding compared with untreated vessels, indicating a tight association of the heparin-like binding sites for the cellular surface. Furthermore, we examined Factor IXa inactivation in aortas of mice deficient in mast cells (w/WV strain [45] , Jackson Laboratory, Bar Harbor, ME), and found that Factor IXa inactivation in these animals was only slightly less in comparison to control mice (data not shown). This suggested that, in the aorta, mast cells provide only marginal amounts of heparin-like glycosaminoglycans promoting antithrombin III anticoagulant activity.
The physiologic significance of the heparin-antithrombin III interaction is implied by the thrombotic diathesis observed in kindreds with antithrombin III molecules interacting abnormally with heparin (46-50). One possible mechanism by which this defect may lead to localized thrombotic events is the impaired ability of antithrombin III to bind to the vessel wall and failure to accelerate inactivation of the coagulation factors. The ability of antithrombin III to bind to heparin-like molecules is particularly important in Factor IX, inhibition which proceeds slowly in the absence of heparin. Thus, vessel wall-antithrombin III interaction may be an important component of the antithrombotic nature of the vascular endothelium. Furthermore, our data suggest that pathophysiological states leading to abnormalities of vessel wall heparin-like glycosaminoglycans may predispose an area of the vessel to thrombosis by impairing antithrombin III binding.
